Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-CMV + Nivolumab in Pediatric and Young Adult Glioma, Medulloblastoma, and Ependymoma
NCT06639607Phase 2Suspended
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Aug 2031
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PEP-CMV in diffuse midline glioma (DMG), glioma, medulloblastoma and 1 more (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Proportion of patients with unacceptable toxicity at 42 days. Started Nov 2026; status: suspended.
02
Drugs
PEP-CMV
03
Conditions
diffuse midline glioma (DMG)gliomamedulloblastomaependymoma
Beyond the preview
Go deeper on NCT06639607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639607.